<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24621930</PMID>
<DateCompleted>
<Year>2015</Year>
<Month>05</Month>
<Day>29</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Electronic-eCollection">
<Journal>
<ISSN IssnType="Electronic">1932-6203</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>9</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>PloS one</Title>
<ISOAbbreviation>PLoS ONE</ISOAbbreviation>
</Journal>
<ArticleTitle>Increased microRNA-630 expression in gastric cancer is associated with poor overall survival.</ArticleTitle>
<Pagination>
<MedlinePgn>e90526</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0090526</ELocationID>
<Abstract>
<AbstractText>MicroRNAs are noncoding RNAs that regulate multiple cellular processes during cancer progression. Among various microRNAs, MiR-630 has recently been identified to be implicated in many critical processes in human malignancies. We aimed to investigate the significance and prognostic value of miR-630 in human gastric cancer. Gastric cancer and adjacent normal specimens from 236 patients from who had not received neoadjuvant chemotherapy were collected. The expression of miR-630 was investigated by quantitative real-time PCR assay and its association with overall survival of patients was analyzed by statistical analysis. MiR-630 expression level was significantly elevated in gastric cancer in comparison to adjacent normal specimens. It is also proved that miR-630 expression was to be associated with gastric cancer invasion, lymph node metastasis, distant metastasis and TNM stage. In addition, survival analysis proved that elevated miR-630 expression was associated with poor overall survival of patients. Multivariate survival analysis also proved that miR-630 was an independent prognostic marker after adjusted for known prognostic factors. The present study proved the over-expression of miR-630 and its association with tumor progression in human gastric cancer. It also provided the first evidence that miR-630 expression was an independent prognostic factor for patients with gastric cancer, which might be a potential valuable biomarker for gastric cancer. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Chu</LastName>
<ForeName>Dake</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Cancer Biology and Xijing Hospital of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China; State Key Laboratory of Cancer Biology and Department of Biochemistry and Molecular Biology, Fourth Military Medical University, Xi'an, Shaanxi, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhao</LastName>
<ForeName>Zhengwei</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Department of General Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Yunming</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Affair, General Hospital of Chengdu Military Region, Chengdu, Sichuan, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Jipeng</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Cancer Biology and Xijing Hospital of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zheng</LastName>
<ForeName>Jianyong</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Cancer Biology and Xijing Hospital of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Weizhong</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Cancer Biology and Xijing Hospital of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhao</LastName>
<ForeName>Qingchuan</ForeName>
<Initials>Q</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Cancer Biology and Xijing Hospital of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ji</LastName>
<ForeName>Gang</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>State Key Laboratory of Cancer Biology and Xijing Hospital of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>03</Month>
<Day>12</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>PLoS One</MedlineTA>
<NlmUniqueID>101285081</NlmUniqueID>
<ISSNLinking>1932-6203</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C548399">MIRN630 microRNA, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014408">Biomarkers, Tumor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035683">MicroRNAs</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013274">Stomach Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016019">Survival Analysis</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2013</Year>
<Month>09</Month>
<Day>14</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2014</Year>
<Month>02</Month>
<Day>03</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2014</Year>
<Month>3</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2014</Year>
<Month>3</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2015</Year>
<Month>5</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">24621930</ArticleId>
<ArticleId IdType="doi">10.1371/journal.pone.0090526</ArticleId>
<ArticleId IdType="pii">PONE-D-13-37803</ArticleId>
<ArticleId IdType="pmc">PMC3951214</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Nat Rev Genet. 2004 Jul;5(7):522-31</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15211354</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>World J Gastroenterol. 2006 Jan 7;12(1):17-20</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16440411</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Death Differ. 2011 Jul;18(7):1220-30</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21274007</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>PLoS One. 2013;8(7):e69756</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23936094</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Cancer. 2010 Apr;46(6):1101-10</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20219351</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2012 Mar 15;11(6):1247-59</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22356768</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>World J Gastroenterol. 2011 Oct 21;17(39):4421-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22110269</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Mol Sci. 2013;14(7):14171-84</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23880861</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Postgrad Med J. 2005 Jul;81(957):419-24</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15998815</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>PLoS One. 2013;8(6):e64707</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23785404</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Diagn Pathol. 2013;8:102</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23786758</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biochem Mol Toxicol. 2012 Feb;26(2):79-86</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22162084</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Cancer. 2013;4(3):281-95</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23459799</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Tumour Biol. 2013 Dec;34(6):3705-12</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23873106</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Rev Cancer. 2011 Dec;11(12):849-64</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22113163</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Cancer. 2002 Jan;38(1):99-166</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11750846</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncol Lett. 2010 Nov;1(6):935-940</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22870090</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Methods Mol Biol. 2006;342:19-32</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16957364</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Oncol. 2013 Oct;43(4):985-94</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23939688</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Appl Genet. 2010;51(4):501-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21063068</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>EMBO Mol Med. 2012 Mar;4(3):143-59</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22351564</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2010 Jan 1;70(1):36-45</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20028859</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur Urol. 2011 May;59(5):671-81</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21296484</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Gastric Cancer. 2013 Apr;16(2):121-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22527183</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>PLoS One. 2013;8(5):e61015</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23675407</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>CA Cancer J Clin. 2013 Jan;63(1):11-30</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23335087</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Rev Genet. 2011 Dec;12(12):861-74</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22094949</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>World J Gastroenterol. 2012 Mar 21;18(11):1262-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22468091</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Anticancer Res. 2008 Mar-Apr;28(2A):907-11</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18507035</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>PLoS One. 2012;7(11):e50966</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23226435</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>CA Cancer J Clin. 2013 May;63(3):151-66</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23386565</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21296855</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2005 Sep;4(9):1179-84</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16096373</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2010 Mar 1;70(5):1793-803</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20145152</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>